Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA

Targeted α therapy (TAT) is a promising tool in the therapy of cancer. The radionuclide (213)Bi(III) shows favourable physical properties for this application, but the fast and stable chelation of this metal ion remains challenging. Herein, we demonstrate that the mesocyclic chelator AAZTA quickly c...

Descripción completa

Detalles Bibliográficos
Autores principales: Horváth, Dávid, Vágner, Adrienn, Szikra, Dezsö, Trencsényi, György, Demitri, Nicola, Guidolin, Nicol, Maiocchi, Alessandro, Ghiani, Simona, Travagin, Fabio, Giovenzana, Giovanni B., Baranyai, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828418/
https://www.ncbi.nlm.nih.gov/pubmed/36073561
http://dx.doi.org/10.1002/anie.202207120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828418/
https://www.ncbi.nlm.nih.gov/pubmed/36073561
http://dx.doi.org/10.1002/anie.202207120

Ejemplares similares